Related Experiment Videos
Insulin detemir. Novo Nordisk
1Istituto di Chimica Farmaceutica e Tossicologica, University of Milan, Viale Abruzzi 42, 20131, Milano, Italy. daniela.barlocco@unimi.it
Current Opinion in Investigational Drugs (London, England : 2000)
|June 18, 2003
Abstract:
Insulin detemir (NN-304) is a soluble, long-acting insulin analog being developed by Novo Nordisk for the potential treatment of type 1 and 2 diabetes. As of February 2003, Novo Nordisk was expecting both US and EU approval in the first half of 2004. In December 2002, Novo Nordisk submitted an NDA to the FDA and an NDS to the Canadian Biologics & Genetics Therapeutic Directorate for the approval of insulin detemir for the treatment of diabetes mellitus.